ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
104,766.15
0.03%
S&P 500
6,101.24
-0.29%
Dow Jones
44,424.25
-0.32%
US Dollar vs Yen
155.995
0.00%
Brent Oil
77.625
0.00%
Registration Strip Icon for charts 登録してリアルタイムのチャート、分析ツール、価格を入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Precision BioSciences Inc (DTIL)

  7. Precision BioSciences Inc (DTIL) ニュース

DTIL

Precision BioSciences (DTIL)

Precision BioSciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:DTIL
日付受信時刻ニュースソース見出しコード企業名
2025/01/2505 : 10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2311 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2305 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2305 : 13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/2206 : 19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2025/01/1000 : 01Business WirePrecision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
2025/01/0922 : 00Business WireiECURE Reports Complete Clinical Response in First Infant Dosed with its In Vivo Gene Editing Candidate ECUR-506 in an Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) DeficiencyNASDAQ:DTILPrecision BioSciences Inc
2025/01/0822 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
2025/01/0221 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/3121 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/3121 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/3020 : 10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/12/1821 : 01Business WirePrecision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
2024/11/2206 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/2121 : 01Business WirePrecision BioSciences to Participate in Upcoming November Investor ConferencesNASDAQ:DTILPrecision BioSciences Inc
2024/11/1521 : 00Business WirePrecision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis BNASDAQ:DTILPrecision BioSciences Inc
2024/11/0609 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0609 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0609 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0505 : 51Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0505 : 49Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DTILPrecision BioSciences Inc
2024/11/0421 : 15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DTILPrecision BioSciences Inc
2024/11/0421 : 15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DTILPrecision BioSciences Inc
2024/11/0421 : 01Business WirePrecision BioSciences Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:DTILPrecision BioSciences Inc
2024/10/2920 : 01Business WirePrecision BioSciences to Report Third Quarter Results on November 4, 2024NASDAQ:DTILPrecision BioSciences Inc
2024/10/2820 : 01Business WirePrecision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024NASDAQ:DTILPrecision BioSciences Inc
2024/10/2505 : 15Business WirePrecision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual CongressNASDAQ:DTILPrecision BioSciences Inc
 Showing the most relevant articles for your search:NASDAQ:DTIL

最近閲覧した銘柄

BIT
P1SRA7
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有